tirzepatide effects on brain prevents neurodegeneration through multiple molecular pathways | Journal of Translational Medicine Tirzepatide May Only Temporarily Suppress

Month-over-month ADM prescribing increased in January, remained stable in February, and increased again in March 2026

Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)

In our study, we confirmed that ACTL6A is a cotranscription factor in the NRF2-dependent regulation of GCLC

Patients with variants linked to rapid response may benefit from different timing or dose-escalation pacing, while those with lower genetic sensitivity often need patience and consistency as medication accumulates

So on paper, tirzepatide tends to edge out semaglutide on average weight loss

Domestic suppliers also tend to maintain better accountability than overseas operations that may be difficult to contact if issues arise